Seminars in Nuclear Medicine
Volume 36, Issue 3 , Pages 194-205 , July 2006

Respective Roles of Thyroglobulin, Radioiodine Imaging, and Positron Emission Tomography in the Assessment of Thyroid Cancer

  • Peter Lind, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Peter Lind, MD, Professor of Nuclear Medicine, Head, Department of Nuclear Medicine and Endocrinology, PET/CT Center Klagenfurt, St. Veiterstr. 47, A-9020 Klagenfurt, Austria
    • ,
  • Susanne Kohlfürst, MD

References 

  1. Lind P , Kumnig G , Heinisch M , et al.   Iodine supplementation in Austria (methods and results) . Thyroid . 2002;12:903–907
  2. Rojewski MT , Gharib H . Nodular thyroid disease. Evaluation and management . N Engl J Med . 1985;313:428–436
  3. Watters DAK , Ahuya AT , Evans RM , et al.   Role of ultrasound in the management of thyroid nodules . Am J Surg . 1992;164:654–657
  4. Gharib H , Goellner JR , Johnson DA . Fine needle aspiration cytology of the thyroid (a 12 year experience with 11,000 biopsies) . Clin Lab Med . 1993;13:699–709
  5. Carmeci C , Jeffrey RB , McDougall IR , et al.   Ultrasound-guided fine-needle aspiration biopsy of thyroid masses . Thyroid . 1998;8:283–289
  6. Mikosch P , Gallowitsch HJ , Kresnik E , et al.   Value of ultrasound-guided fine needle aspiration biopsy of thyroid nodules in an endemic goitre area . Eur J Nucl Med . 2002;27:62–69
  7. Lind P . Multi-tracer imaging of thyroid nodules (is there a role in the preoperative assessment of nodular goiter ?) . (editorial) Eur J Nucl Med . 1999;26:795–797
  8. El-Desouki M . Tl 201 thyroid imaging in differentiating benign from malignant thyroid nodules . Clin Nucl Med . 1991;16:225–230
  9. Sundran FX , Mack P . Evaluation of thyroid nodules for malignancy using T-99m-sestamibi . Nucl Med Commun . 1995;16:687–693
  10. Mezosi E , Bajnok I , Gyory F , et al.   The role of Tc-99m methoxy-isobutyl-isonitrile (MIBI) scintigraphy in the differential diagnosis of cold thyroid nodules . Eur J Nucl Med . 1999;26:798–803
  11. Kresnik E , Gallowitsch HJ , Mikosch P , et al.   Tc-99m MIBI scintigraphy of thyroid nodules in an endemic goiter area . J Nucl Med . 1997;38:62–65
  12. Kresnik E , Gallowitsch HJ , Mikosch P , et al.   Evaluation of thyroid nodules with Tc-99m tetrofosmin dual phase scintigraphy . Eur J Nucl Med . 1997;24:716–721
  13. Joensuu H , Ahonen A , Klemi PJ . 18F-fluorodeoxyglucose imaging in the preoperative diagnosis of thyroid malignancy . Eur J Nucl Med . 1988;13:502–506
  14. Bloom AD , Adler LP , Shuck JM . Determination of malignancy of thyroid nodules with positron emission tomography . Surgery . 1993;114:728–734
  15. Uematsu H , Sadato N , Ohtsubo T , et al.   Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors . J Nucl Med . 1998;39:453–459
  16. Mitchell JC , Grant F , Evenson AR , et al.   Preoperative evaluation of thyroid nodules with (18)FDG-PET/CT . Surgery . 2005;138:1166–1175
  17. Sasaki M , Ichiya Y , Kuwabara Y , et al.   An evaluation of FDG PET in the detection and differentiation of thyroid tumors . Nucl Med Commun . 1997;18:957–963
  18. Kresnik E , Gallowitsch HJ , Mikosch P , et al.   Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area . Surgery . 2003;133:294–299
  19. Van Herle AJ , Uller RP . Elevated thyroglobulin (a marker of metastases in differentiated thyroid carcinoma) . J Clin Invest . 1975;56:272–276
  20. Pacini F , Lari R , Mazzeo S , et al.   Diagnostic value of single serum thyroglobulin determination on and off thyroid supressive therapy in the follow-up of patients with differentiated thyroid cancer . Clin Endocrinol (Oxf) . 1985;23:405–408
  21. Ronga G , Fiorentino A , Paserio E , et al.   Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the postsurgical follow up of differentiated thyroid carcinoma? . J Nucl Med . 1990;31:1766–1771
  22. Ozata M , Suzuki S , Miyamoto T , et al.   Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer . J Clin Endocrinol Metab . 1994;79:98–105
  23. Spencer CA , Takeuchi M , Kazarosyan M , et al.   Serum thyroglobulin autoantibodies (prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma) . J Clin Endocrinol Metab . 1998;83:1121–1127
  24. Pacini F . Follow up of differentiated thyroid cancer . Eur J Nucl Med . 2002;(suppl 2):S492–S496
  25. Westbury C , Vini L , Fisher C , et al.   Recurrent differentiated thyroid cancer without elevation of thyroglobulin . Thyroid . 2000;10:171–176
  26. Harder W , Lind P , Molnar M , et al.   Thallium-201 uptake with negative I-131 scintigraphy and serum thyroglobulin in metastatic oxyphilic papillary thyroid carcinoma . J Nucl Med . 1997;39:236–238
  27. Cailaux AF , Baudin E , Travagli JP , et al.   Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? . J Clin Endocrinol Metab . 2000;85:175–178
  28. Pacini F , Cappezone M , Elisei R , et al.   Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated thyroglobulin levels after initial treatment . J Clin Endocrinol Metab . 2002;87:1492–1495
  29. Kohlfuerst S , Igerc I , Lind P . Recombinant thyrotropin is helpful in the follow up and I-131 therapy of patients wirh thyroid cancer (a report of the results and benefits using recombinant human thyrotropin in clinical routine) . Thyroid . 2005;15:371–376
  30. Pacini F , Lippi F . Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH) (serum thyroglobulin measurement) . J Endocrinol Invest . 1999;22(suppl):25–29
  31. Robbins RJ , Chon JT , Fleisher M , et al.   Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itsself, to monitor for residual thyroid carcinoma . J Clin Endocrinol Metab . 2002;87:3242–3247
  32. Wartofsky L . Management of low-risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin . Thyroid . 2002;12:583–590
  33. Menzel C , Zaplatnikov K , Diel M , et al.   The influence of functional imaging in differentiated thyroid cancer . Nucl Med Commun . 2004;25:239–243
  34. Schlumberger M , Berg G , Cohen O , et al.   Follow-up of low risk patients with differentiated thyroid carcinoma (a European perspective) . Eur J Endocrinol . 2004;150:105–112
  35. Haber RS . Role of ultrasonography in the diagnosis and management of thyroid cancer . Endocr Pract . 2000;6:396–400
  36. Mazzaferri E , Robbins RJ , Spencer CA , et al.   A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma . J Clin Endocrinol Metab . 2003;88:1433–1441
  37. Fatourechi V , Hay ID . Treating the patient with differentiated thyroid cancer with thyroglobulin-positive, iodine-131 diagnostic scan negative metastases (including comments on the role of serum thyroglobulin monitorinog in tumor surveillance) . Semin Nucl Med . 2000;30:107
  38. Mazzaferri E , Kloos RT . Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? . J Clin Endocrinol Metab . 2002;87:1490–1498
  39. Intenzo CM , Jabbour S , Dam HQ , et al.   Changing concepts in the management of differentiated thyroid cancer . Semin Nucl Med . 2005;35:257–265
  40. Lind P , Igerc I , Kohlfuerst S . Diagnosis, treatment and follow-up in case of differentiated thyroid cancer . Wien Med Wschr . 2005;19/20:429–435
  41. Waxman A , Ramanna L , Chapman N , et al.   The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation. Concise communication . J Nucl Med . 1981;22:861–865
  42. Lind P . I-131 whole body scintigraphy in thyroid cancer patients . Q J Nucl Med . 1999;43:188–194
  43. Dadparvar S , Krishna L , Slizofski WJ , et al.   The role of Iodine-131 and Thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma . Cancer . 1993;11:3767–3773
  44. Franceschi M , Kusic Z , Franceschi D , et al.   Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma . J Nucl Med . 1996;37:446–451
  45. Van-Sorge-Van Boxtel RAV , Van Eck-Smit BLF , Goslings BM . Comparison of serum thyroglobulin, I-131 and Tl-201 scintigraphy in the postoperative follow up differentiated thyroid cancer . Nuc Med Commun . 1992;14:365–372
  46. Filesi M , Signore A , Ventroni G , et al.   Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases . J Nucl Med . 1998;39:1542–1546
  47. Spies WG , Wojtowicz CH , Spies SM , et al.   Value of post-therapy whole-body 131-I imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose 131-I therapy . Clin Nucl Med . 1989;14:793–800
  48. Sutter CW , Masilungan BG , Stadalnic RC . False positive results of 131-I whole-body scan in patients with thyroid cancer . Semin Nucl Med . 1995;25:279–282
  49. Lubin E , Mechlis-Frish S , Zatz S , et al.   Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma . J Nucl Med . 1994;35:257–262
  50. Simpson WJ , Panzarella T , Curruthers JS , et al.   Papillary and follicular thyroid cancer; impact of treatment in 1578 patients . Int J Rad Oncol Biol Phys . 1988;14:1063–1075
  51. Leger FA , Izembart M , Dagousset F , et al.   Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma . Eur J Nucl Med . 1998;25:242–246
  52. Coakly AJ . Thyroid stunning . Eur J Nucl Med . 1998;25:203–204
  53. Pineda JD , Lee T , Ain K , et al.   I-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan . J Clin Endocrinol Metab . 1995;80:1488–1492
  54. Lind P . Should high hTg levels in the absence of iodine uptake be treated . Eur J Nucl Med . 2003;30:157–160
  55. Pace L , Klain M , Albanese C , et al.   Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment . Eur J Nucl Med Mol Imaging . 2006;33:179–183
  56. Ma C , Kuang A , Xie J , et al.   Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning . J Nucl Med . 2005;46:1473–1480
  57. Joensuu H , Ahonen A . Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose . J Nucl Med . 1987;28:910–914
  58. Lind P , Gallowitsch HJ , Mikosch P , et al.   Comparison of different tracers in the follow up of differentiated thyroid carcinoma . Act Med Austriaca . 1999;26:115–118
  59. Reske SN , Kotzerke J . FDG PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, “Onko PET III”, 21. July and 19. September 2000 . Eur J Nucl Med . 2001;28:1707–1723
  60. Feine U , Lizenmayer R , Hanke JP , et al.   Fluorine-18 FDG and iodine-131 uptake in thyroid cancer . J Nucl Med . 1996;37:1468–1472
  61. Grünwald F , Menzel C , Bender H , et al.   Comparison of 18FDG-PET with 131-iodine and 99m Tc-sestamibi scintigraphy in differentiated thyroid cancer . Thyroid . 1997;7:327–335
  62. Lind P , Kresnik E , Kumnig G , et al.   F-18-FDG PET in following up thyroid cancer . Acta Med Austriaca . 2003;30:17–21
  63. Conti PS , Durski JM , Bacqai F , et al.   Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomograpgy . Thyroid . 1999;9:797–804
  64. Altenvoerde G , Lerch H , Kuwert T , et al.   Positron emission tomograpgy with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels and negative iodine scans . Langenbecks Arch Surg . 1998;383:160–163
  65. Schluetter B , Bohuslavizki KH , Beyer W , et al.   Impact of FDG PET on patients with well differentiated thyroid cancer who present with elevated thyroglobulin and negative I-131 scan . J Nucl Med . 2001;42:71–76
  66. Moog F , Linke R , Manthey N , et al.   Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma . J Nucl Med . 2000;41:1989–1995
  67. Petrich T , Börner AR , Weckesser E . Follow up of thyroid cancer patients using rhTSH-preliminary results . Nucl Med . 2001;40:7–14
  68. Ruf J , Lehmkuhl L , Bertram H , et al.   Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma . Nucl Med Commun . 2004;25:1177–1182
  69. Lind P , Igerc I . PET and PET/CT in the following up of thyroid cancer patients . In:  Langsteger W ,  Sungler P ,  Lind P , et al. editor. Thyroid cancer four 2004 . Vienna: KOOP; 2004; (CD ROM)
  70. Beyer T , Townsend DW , Brun T , et al.   A combination ofPET/CT scanner for clinical oncology . J Nucl Med . 2000;41:1369–1379
  71. Schöder H , Erdi YE , Larson SM , et al.   PET/CT (a new imaging technology in nuclear medicine) . Eur J Nucl Med Mol Immaging . 2003;30:1419–1437
  72. Hausegger K , Reinprecht P , Kau T , et al.   Clinical experience with a commercially available negative oral contrast medium in PET/CT . Fortschr Roentgenstr . 2005;177:796–799
  73. Lardinois D , Weder W , Hany TF , et al.   Staging of non-small-cell lung-cancer wirth integrated positron emissiontomography and computed tomography . N Engl J Med . 2003;348:2500–2507
  74. Burger I , Görres G , von Shulthess G , et al.   PET/CT (diagnostic improvement in recurrent colorectal carcinoma compared to PET alone) . Radiology . 2002;225:424
  75. Beyer T . Towards truly integrated hardware fusion with PET/CT . Nucl Med . 2005;44(suppl 1):S5–S12
  76. Pietrzyk U . Does PET/CT render software registration obsolete? . Nucl Med . 2005;44(suppl 1):S13–S17
  77. Czernin J , Auerbach MA . Clinical PET/CT imaging . Nucl Med . 2005;44(suppl 1):S18–S23
  78. Ong SC , Ng DC , Sundram FX . Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomographycomputed tomography in thyroid carcinoma patients with elevated thyroglobulin but negative iodine-131 whole body scans . Singapore Med . 2005;46:297–301
  79. Nahas Z , Goldenberg D , Fakhry C , et al.   The role of positron emission tomographycomputed tomography in the management of recurrent papillary thyroid carcinoma . Laryngoscope . 2005;115:237–243
  80. Sgouros G , Kolbert KS , Sheik A , et al.   Patient- specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software . J Nucl Med . 2004;48:1366–1372
  81. Freudenberg LS , Antoch G , Jentzen G , et al.   Value of 124-I-PET/CT in staging of patients with differentiated thyroid cancer . Eur Radiol . 2004;14:2092–2098
  82. Lind P . Differentiated thyroid cancer . In:  Ell PJ ,  Gambhir SS editor. Nuclear Medicine in Clinical Diagnosis and Treatment . Edinburgh: Churchill Livingstone; 2004;p. 145–164

PII: S0001-2998(06)00015-8

doi: 10.1053/j.semnuclmed.2006.03.002

Seminars in Nuclear Medicine
Volume 36, Issue 3 , Pages 194-205 , July 2006

Article Tools

* Image Usage & Resolution